Isodiol International Inc. Commences Process to List on the Australian Stock Exchange
September 12, 2017 – Vancouver, BC –Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”) a global cannabis innovator specializing in the development of pharmaceutical and consumer products announces that it has initiated the process of obtaining a secondary listing on the Australian Stock Exchange (ASX) and expects this process to be…
Read MoreIsodiol International Inc. Announces Launching Phytoceutical Division
September 5, 2017 – Vancouver, BC –Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”) a global cannabis innovator specializing in the development of pharmaceutical and consumer products announces that it is proud to be launching a new Phytoceutical Division that will focus on cannabinoids and terpenes derived from non-cannabis sources. Proprietary…
Read MoreIsodiol International Inc Announces Distribution Agreement for South America
August 30th, 2017 – Vancouver, BC –Isodiol International Inc. (CSE: ISOL) (OTC: LAGBF) (FSE: LB6A.F) (the “Company” or “Isodiol”) a global cannabinoid innovator specializing in the development of pharmaceutical and consumer products announces it has signed a distribution partnership with FarmaUSA™, a leading global wholesale distributor of imported pharmaceutical products in South America. This is the latest…
Read MoreIsodiol International Inc. Reports Q1 Unaudited Financial Statements
August 29th, 2017 – Vancouver, BC –Isodiol International Inc. (CSE: ISOL) (OTC: LAGBF) (FSE: LB6A.F) (the “Company” or “Isodiol”) a global cannabis innovator specializing in the development of pharmaceutical and consumer products reports Q1 revenue for the period ended June 30, 2017 of $2,740,542 compared to Q1 revenue in 2016 of $47,185. The substantial increase in…
Read MoreIsodiol International Inc. Provides Sponsorship At The US Autism Asperger Association Conference
August 28, 2017 – Vancouver, Canada – Isodiol International Inc. (CSE: ISOL) (OTC: LAGBF) (FSE: LB6A.F) (the “Company” or “Isodiol”) a global cannabis innovator, specializing in the development of pharmaceutical and consumer products, announces it proudly exhibited at the US Autism & Asperger Association (USAAA) (usautism.org/conferences) conference this past weekend in Portland, Oregon and sponsored Dr.…
Read MoreIsodiol International Inc. Announces $25,000,000 Convertible Debenture Financing
August 21, 2017 – Vancouver, Canada – Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”) a global cannabis innovator, specializing in the development of pharmaceutical and consumer products announces it has signed a convertible debenture financing for $25,000,000 CDN with Alumina Partners. Marcos Agramont, CEO of Isodiol stated, “Our focus remains…
Read MoreIsodiol International Inc. Announces Conference Sponsorship in Brazil
August 9, 2017 – Vancouver, Canada – Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”) a global cannabis innovator, specializing in the development of pharmaceutical and consumer products announces it is proudly sponsoring the 50th Anniversary of IV International and XXIV Brazilian Congress of ABENEPI (Brazilian Association of Neurology and Child Psychiatry and Related…
Read MoreIsodiol International Inc. Corporate Update
August 4, 2017 – Vancouver, Canada – Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”) a global cannabis innovator, specializing in the development of pharmaceutical and consumer products announces unaudited July 2017 revenue numbers of its wholly owned subsidiary ISO International LLC of $1,358,787 USD. Marcos Agramont CEO of Isodiol stated,…
Read MoreIsodiol International Inc. Announces OTC Symbol Change
August 2, 2017 – Vancouver, Canada – Isodiol International Inc. (CSE: ISOL) (OTC: LAGBF) (FSE: LB6A.F) (“Isodiol or the “Company“) is pleased to announce that the Financial Industry Regulatory Authority, Inc. (“FINRA”) has approved the Company’s OTC voluntary symbol change from “LAGBF” to “ISOLF” to better reflect the Company’s current name. The changes will be…
Read MoreIsodiol International Inc. announces unaudited quarterly profit of Iso International LLC.
July 26, 2017 – Vancouver, Canada – Isodiol International Inc. (CSE: ISOL) (OTC: LAGBF) (FSE: LB6A.F) (the “Company” or “Isodiol”) a global cannabis innovator, specializing in the development of pharmaceutical and consumer products, announces the operational numbers of its wholly-owned subsidiary for the period from April 1, 2017 to June 30, 2017. Iso International LLC…
Read MoreIsodiol International Inc. signs definitive licensing agreement with Canopy Growth Corporation for Canadian and international distribution
July 20, 2017 – Vancouver, Canada – Isodiol International Inc. (CSE: ISOL) (OTC: LAGBF) (FSE: LB6A.F) (the “Company” or “Isodiol”) a global cannabis innovator specializing in the development of pharmaceutical and consumer products is pleased to announce it has signed a licensing agreement with Canopy Growth Corporation (“Canopy”) (TSX:WEED) (https://www.canopygrowth.com). Canopy Growth is the world’s…
Read MoreIsodiol International Inc. Announces Corporate Update
July 11, 2017 – Vancouver, Canada – Isodiol International Inc. (CSE: ISOL) (OTC: LAGBF) (FSE: LB6A.F) (the “Company” or “Isodiol”) a global cannabis innovator specializing in the development of pharmaceutical and consumer products, today released its unaudited consolidated sales figures for the month of June 2017. The company recorded sales of $1,843,173 CAD for the…
Read MoreIsodiol International Inc. receives regulatory (ANVISA) approval for Isoderm for the treatment of Epilepsy and Parkinson’s
July 6, 2017 – Vancouver, Canada – Isodiol International Inc. (CSE: ISOL) (OTC: LAGBF) (FSE: LB6A.F) (the “Company” or “Isodiol”) a global cannabis innovator specializing in the development of pharmaceutical and consumer products is pleased to announce it has received approval from the Brazilian Health Regulatory Agency (ANVISA) for the approval of its pharmaceutical grade…
Read MoreIsodiol International Inc. establishes operations in Mexico and will commence shipment of cannabinol products
June 21, 2017 – Vancouver, Canada – Isodiol International Inc. (CSE: ISOL) (OTC: LAGBF) (FSE: LB6A.F) (the “Company” or “Isodiol”) a global cannabis innovator specializing in the development of pharmaceutical and consumer products is pleased to announce it has established operations in Mexico and will commence shipment of its Cannabinol products throughout Mexico within the…
Read MoreIsodiol International inc. commences approval process for its pharmaceutical products through the Brazilian Health Regulatory Agency (ANVISA)
June 19, 2017 – Vancouver, Canada – Isodiol International Inc. (CSE: ISOL) (OTC: LAGBF) (FSE: LB6A.F) (the “Company” or “Isodiol”) a global cannabis innovator specializing in the development of pharmaceutical and consumer products is pleased to announce it has initiated the drug approval process through the Brazilian Health Regulatory Agency (ANVISA) for the approval of…
Read More